A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: Multiple Sclerosis
Age: Between 18 - 55 Years
Gender: Male or Female
Have primary-progressive MS, secondary-progressive MS or relapsing-remitting MS
Are on a stable dose of MS medication for at least 6 months or have been in stable condition without and an MS immunotherapy or corticosteroid for at least 6 months